8-K: Silo Pharma Gets Nasdaq Extension on Bid Price Rule

Silo Pharma, Inc. has received an extension from Nasdaq until June 22, 2026, to regain compliance with the minimum $1.00 bid price requirement, avoiding immediate delisting.

Summary

• Silo Pharma, Inc. failed to meet Nasdaq's minimum bid price requirement of $1.00 per share by the initial deadline of December 24, 2025.
• The company received an extension from Nasdaq on December 24, 2025, granting an additional 180 calendar days, until June 22, 2026, to regain compliance.
• Nasdaq's decision was based on the company meeting other continued listing requirements, such as market value of publicly held shares, and its stated intention to cure the deficiency, potentially through a reverse stock split.
• There is no immediate impact on the listing or trading of Silo Pharma's common stock on The Nasdaq Capital Market under the symbol SILO.
• To regain compliance, the common stock's bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days.
• Failure to comply by June 22, 2026, will result in delisting, though the company may appeal.
• Management intends to monitor the stock price and consider options like a reverse stock split.

Sentiment

Score: 4

Explanation: While an extension was granted, the underlying issue of failing to meet the minimum bid price requirement persists, indicating ongoing challenges for the company's stock performance. The need to consider a reverse stock split is generally viewed negatively by investors.

Positives

• Nasdaq granted an extension until June 22, 2026, to regain compliance, preventing immediate delisting.
• The company meets other Nasdaq continued listing requirements, including market value of publicly held shares.
• No immediate effect on the listing or trading of the company's common stock.

Negatives

• Failed to meet the initial Nasdaq minimum bid price requirement of $1.00 per share by the December 24, 2025 deadline.
• Continued non-compliance could lead to delisting from The Nasdaq Capital Market if the bid price requirement is not met by June 22, 2026.

Risks

• Potential delisting from The Nasdaq Capital Market if the minimum bid price of $1.00 per share is not maintained for 10 consecutive business days by June 22, 2026.
• The need to potentially implement a reverse stock split, which can sometimes be viewed negatively by investors and impact share liquidity.

Future Outlook

The company intends to monitor the closing bid price of its common stock and may consider implementing available options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement by the extended deadline of June 22, 2026.

Management Comments

• "The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities during the second compliance period, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules."

Industry Context

This announcement reflects a common challenge faced by smaller or developing public companies, particularly in sectors like biotechnology or pharmaceuticals (implied by "Silo Pharma"), where stock prices can be volatile or remain below listing thresholds. Maintaining Nasdaq listing is crucial for liquidity and investor confidence, and extensions are often granted if companies demonstrate a path to compliance and meet other listing criteria.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the company's Nasdaq listing status and potential dilution or share price impact from a reverse stock split.
• Investors: May view the ongoing non-compliance and the need for an extension as a negative signal regarding the company's financial health or market perception.

Next Steps

• Monitor the closing bid price of common stock.
• Consider implementing available options, including a reverse stock split, to regain compliance.
• If compliance is not achieved by June 22, 2026, the company may appeal Nasdaq's delisting determination.

Key Dates

Recommendation

The company received an extension, which temporarily alleviates the immediate threat of delisting, but the underlying issue of failing to meet the minimum bid price requirement remains. The potential for a reverse stock split introduces uncertainty. Investors should hold to observe if the company can successfully regain compliance by the new deadline and how any potential reverse stock split is executed, as the immediate delisting risk is mitigated for now.

Keywords

Nasdaq, Delisting, Minimum Bid Price, Silo Pharma, SILO, Stock Market Compliance, Reverse Stock Split, Extension, 8-K Filing